CN114767718A - 突变型博德特氏菌属菌株及其使用方法 - Google Patents
突变型博德特氏菌属菌株及其使用方法 Download PDFInfo
- Publication number
- CN114767718A CN114767718A CN202210315642.5A CN202210315642A CN114767718A CN 114767718 A CN114767718 A CN 114767718A CN 202210315642 A CN202210315642 A CN 202210315642A CN 114767718 A CN114767718 A CN 114767718A
- Authority
- CN
- China
- Prior art keywords
- pertussis
- composition
- deficient
- prn
- bordetella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000588807 Bordetella Species 0.000 title abstract description 52
- 238000000034 method Methods 0.000 title abstract description 43
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 64
- 201000005702 Pertussis Diseases 0.000 claims abstract description 60
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims abstract description 58
- 230000002950 deficient Effects 0.000 claims abstract description 55
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 208000037883 airway inflammation Diseases 0.000 claims abstract description 27
- 230000002238 attenuated effect Effects 0.000 claims abstract description 25
- 238000011161 development Methods 0.000 claims abstract description 17
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 16
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- APUIQTDTBPKWKE-RNPGEKFLSA-N (2r,6s)-6-[[(4r)-4-[[(2s)-2-[2-[[(1r,2s,3r,4r,5r)-4-acetamido-2-[(2s,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,8-dioxabicyclo[3.2.1]octan-3-yl]oxy]propanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-2-amino-7-[[(2r)-2-am Chemical compound O([C@@H]1[C@H]2CO[C@H](O2)[C@H](NC(C)=O)[C@H]1OC(C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@@H](N)C(O)=O)C(=O)NC(=O)[C@H](N)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O APUIQTDTBPKWKE-RNPGEKFLSA-N 0.000 claims description 24
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 24
- 239000003053 toxin Substances 0.000 claims description 21
- 231100000765 toxin Toxicity 0.000 claims description 21
- 239000000304 virulence factor Substances 0.000 claims description 14
- 230000007923 virulence factor Effects 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 108060000200 adenylate cyclase Proteins 0.000 claims description 7
- 102000030621 adenylate cyclase Human genes 0.000 claims description 7
- 239000002158 endotoxin Substances 0.000 claims description 7
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 230000002500 effect on skin Effects 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 22
- 230000000241 respiratory effect Effects 0.000 abstract description 3
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 72
- 210000004072 lung Anatomy 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 22
- 230000000172 allergic effect Effects 0.000 description 21
- 208000010668 atopic eczema Diseases 0.000 description 21
- 108700012359 toxins Proteins 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 101150006855 PRN gene Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 230000028993 immune response Effects 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 206010040893 Skin necrosis Diseases 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000036039 immunity Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010039085 Rhinitis allergic Diseases 0.000 description 5
- 201000010105 allergic rhinitis Diseases 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000007492 two-way ANOVA Methods 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 101150103308 ampG gene Proteins 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 230000002327 eosinophilic effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000001987 Bordet-Gengou agar Substances 0.000 description 3
- 208000018150 Bordetella infection Diseases 0.000 description 3
- 241000588780 Bordetella parapertussis Species 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010013639 Peptidoglycan Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 208000037884 allergic airway inflammation Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000001823 molecular biology technique Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 210000005058 airway cell Anatomy 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 2
- 229960002329 methacholine Drugs 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229940066827 pertussis vaccine Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- RADQQIMFQHYCBI-UHFFFAOYSA-N 6-[[4-[2-[2-[2-acetamido-4-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,6-dihydroxy-1-oxohexan-3-yl]oxypropanoylamino]propanoylamino]-4-carboxybutanoyl]amino]-2-amino-7-(1-carboxyethylamino)-7-oxoheptanoic acid Chemical class OC(=O)C(N)CCCC(C(=O)NC(C)C(O)=O)NC(=O)CCC(C(O)=O)NC(=O)C(C)NC(=O)C(C)OC(C(NC(C)=O)C=O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1NC(C)=O RADQQIMFQHYCBI-UHFFFAOYSA-N 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- -1 IFNγ Proteins 0.000 description 1
- 229940124915 Infanrix Drugs 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000008267 Peanut Hypersensitivity Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010073429 Type V Secretion Systems Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 201000010853 peanut allergy Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 208000034280 venom allergy Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314843P | 2016-03-29 | 2016-03-29 | |
| US62/314,843 | 2016-03-29 | ||
| CN201780021384.7A CN109069535B (zh) | 2016-03-29 | 2017-03-29 | 突变型博德特氏菌属菌株及其使用方法 |
| PCT/EP2017/057468 WO2017167834A1 (en) | 2016-03-29 | 2017-03-29 | Mutant bordetella strains and methods for use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780021384.7A Division CN109069535B (zh) | 2016-03-29 | 2017-03-29 | 突变型博德特氏菌属菌株及其使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114767718A true CN114767718A (zh) | 2022-07-22 |
Family
ID=58488973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210315642.5A Pending CN114767718A (zh) | 2016-03-29 | 2017-03-29 | 突变型博德特氏菌属菌株及其使用方法 |
| CN201780021384.7A Active CN109069535B (zh) | 2016-03-29 | 2017-03-29 | 突变型博德特氏菌属菌株及其使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780021384.7A Active CN109069535B (zh) | 2016-03-29 | 2017-03-29 | 突变型博德特氏菌属菌株及其使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10682377B2 (enExample) |
| EP (2) | EP4541809A3 (enExample) |
| JP (1) | JP6993984B2 (enExample) |
| CN (2) | CN114767718A (enExample) |
| AU (2) | AU2017242541B2 (enExample) |
| CA (1) | CA3018126A1 (enExample) |
| DK (1) | DK3436034T3 (enExample) |
| ES (1) | ES3027194T3 (enExample) |
| FI (1) | FI3436034T3 (enExample) |
| SG (1) | SG11201807783UA (enExample) |
| WO (1) | WO2017167834A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0707102B1 (pt) * | 2006-03-10 | 2022-05-31 | Institut Pasteur De Lille | Composição imunogênica |
| CA2759280C (en) | 2009-04-28 | 2016-09-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vaccine for prophylaxis or treatment of an allergen-driven airway pathology |
| AU2017242541B2 (en) * | 2016-03-29 | 2022-06-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutant bordetella strains and methods for use |
| CA3077428A1 (en) | 2017-10-18 | 2019-04-25 | Institut Pasteur De Lille | Bordetella strains expressing serotype 3 fimbriae |
| BR112023002549A2 (pt) | 2020-08-14 | 2023-03-07 | Iliad Biotechnologies Llc | Método de fabricação de uma vacina liofilizada compreendendo bactérias bordetella vivas atenuadas e produto de vacina liofilizada |
| CN116635517A (zh) | 2020-11-17 | 2023-08-22 | 伊利亚德生物技术有限公司 | 与神经退行性疾病相关的神经病理的治疗和预防 |
| JP2025525623A (ja) | 2022-07-22 | 2025-08-05 | アンスティチュ ナシヨナル デュ ラ サンテ エト デュ ラ レシェルシェ メディカレ | 慢性閉塞性肺疾患の治療のためのボルデテラ（ｂｏｒｄｅｔｅｌｌａ）菌株の使用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1147259A (zh) * | 1994-04-28 | 1997-04-09 | 武田药品工业株式会社 | 分离百日咳杆菌保护性组分的方法 |
| US6660261B1 (en) * | 1996-10-11 | 2003-12-09 | Institut Pasteur De Lille | Bordetella strain expressing the FHA hybrid, liposomes and vaccines |
| CN101400783A (zh) * | 2006-03-10 | 2009-04-01 | 巴斯德研究院里尔分院 | 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗 |
| WO2010125014A1 (en) * | 2009-04-28 | 2010-11-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vaccine for prophylaxis or treatment of an allergen-driven airway pathology |
| CN102793915A (zh) * | 2012-07-25 | 2012-11-28 | 天津康希诺生物技术有限公司 | 一种无细胞百日咳疫苗的生产方法 |
| WO2013066272A1 (en) * | 2011-11-02 | 2013-05-10 | National University Of Singapore | Effect of an attenuated bordetella strain against allergic disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6713072B1 (en) | 1987-11-02 | 2004-03-30 | Chiron S.R.L. | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
| GB9115332D0 (en) * | 1991-07-16 | 1991-08-28 | Connaught Lab | Manipulation of gene copy number in bordetella |
| FR2718750B1 (fr) | 1994-04-19 | 1996-06-14 | Pasteur Institut | Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants. |
| FR2840319B1 (fr) | 2002-05-30 | 2004-08-20 | Pasteur Institut | Souches de bordetella rendues deficientes par attenuation genetique |
| EP1617805A4 (en) | 2003-04-11 | 2012-07-04 | Medimmune Llc | METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS |
| WO2008058396A1 (en) | 2006-11-15 | 2008-05-22 | Folia Biotech Inc. | Papaya mosaic virus-based vaccines for influenza |
| EP2134359A4 (en) | 2007-02-23 | 2010-06-16 | Penn State Res Found | USE OF A NONVIRULENT BORDETELLA MUTANT AS LIVING VACCINE VECTOR |
| US20100104533A1 (en) | 2007-06-18 | 2010-04-29 | Carter William A | Early intervention of viral infection with immune activators |
| JP5551774B2 (ja) | 2009-06-15 | 2014-07-16 | ナショナル ユニヴァーシティー オブ シンガポール | インフルエンザワクチン、組成物、および使用方法 |
| EP2722338A1 (en) | 2012-10-17 | 2014-04-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel recombinant Bordetella strains |
| AU2017242541B2 (en) * | 2016-03-29 | 2022-06-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutant bordetella strains and methods for use |
-
2017
- 2017-03-29 AU AU2017242541A patent/AU2017242541B2/en active Active
- 2017-03-29 CA CA3018126A patent/CA3018126A1/en active Pending
- 2017-03-29 ES ES17715426T patent/ES3027194T3/es active Active
- 2017-03-29 CN CN202210315642.5A patent/CN114767718A/zh active Pending
- 2017-03-29 JP JP2018551960A patent/JP6993984B2/ja active Active
- 2017-03-29 EP EP25158892.7A patent/EP4541809A3/en active Pending
- 2017-03-29 FI FIEP17715426.7T patent/FI3436034T3/fi active
- 2017-03-29 DK DK17715426.7T patent/DK3436034T3/da active
- 2017-03-29 CN CN201780021384.7A patent/CN109069535B/zh active Active
- 2017-03-29 US US15/472,436 patent/US10682377B2/en active Active
- 2017-03-29 EP EP17715426.7A patent/EP3436034B1/en active Active
- 2017-03-29 SG SG11201807783UA patent/SG11201807783UA/en unknown
- 2017-03-29 WO PCT/EP2017/057468 patent/WO2017167834A1/en not_active Ceased
-
2020
- 2020-04-30 US US16/863,972 patent/US11065276B2/en active Active
-
2021
- 2021-06-02 US US17/337,367 patent/US20210290667A1/en not_active Abandoned
-
2022
- 2022-08-24 AU AU2022221438A patent/AU2022221438B2/en active Active
-
2023
- 2023-06-20 US US18/338,314 patent/US20230381224A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1147259A (zh) * | 1994-04-28 | 1997-04-09 | 武田药品工业株式会社 | 分离百日咳杆菌保护性组分的方法 |
| US6660261B1 (en) * | 1996-10-11 | 2003-12-09 | Institut Pasteur De Lille | Bordetella strain expressing the FHA hybrid, liposomes and vaccines |
| CN101400783A (zh) * | 2006-03-10 | 2009-04-01 | 巴斯德研究院里尔分院 | 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗 |
| WO2010125014A1 (en) * | 2009-04-28 | 2010-11-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vaccine for prophylaxis or treatment of an allergen-driven airway pathology |
| CN102448490A (zh) * | 2009-04-28 | 2012-05-09 | 国家健康与医学研究院 | 用于预防或治疗过敏原引起的气道疾病的疫苗 |
| WO2013066272A1 (en) * | 2011-11-02 | 2013-05-10 | National University Of Singapore | Effect of an attenuated bordetella strain against allergic disease |
| CN102793915A (zh) * | 2012-07-25 | 2012-11-28 | 天津康希诺生物技术有限公司 | 一种无细胞百日咳疫苗的生产方法 |
Non-Patent Citations (2)
| Title |
|---|
| NICOLAS HEGERLE等: "Bordetella pertussis and pertactin-deficient clinical isolates：lessons for pertussis vaccines", 《EXPERT REVIEW OF VACCINES》, pages 1141 * |
| 柯兵兵;徐颖华;侯启明;马霄;: "百日咳鲍特菌黏附分子的研究进展", 中国生物制品学杂志, no. 11, pages 169 - 173 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4541809A3 (en) | 2025-06-25 |
| FI3436034T3 (fi) | 2025-05-08 |
| US11065276B2 (en) | 2021-07-20 |
| EP3436034B1 (en) | 2025-03-26 |
| AU2022221438B2 (en) | 2024-10-03 |
| JP2019513722A (ja) | 2019-05-30 |
| EP3436034A1 (en) | 2019-02-06 |
| US20170283890A1 (en) | 2017-10-05 |
| DK3436034T3 (da) | 2025-05-12 |
| CN109069535B (zh) | 2022-03-18 |
| AU2017242541B2 (en) | 2022-06-30 |
| US10682377B2 (en) | 2020-06-16 |
| JP6993984B2 (ja) | 2022-02-03 |
| CN109069535A (zh) | 2018-12-21 |
| AU2017242541A1 (en) | 2018-10-11 |
| AU2022221438A1 (en) | 2022-10-06 |
| EP4541809A2 (en) | 2025-04-23 |
| US20200323901A1 (en) | 2020-10-15 |
| SG11201807783UA (en) | 2018-10-30 |
| US20210290667A1 (en) | 2021-09-23 |
| ES3027194T3 (en) | 2025-06-13 |
| WO2017167834A1 (en) | 2017-10-05 |
| CA3018126A1 (en) | 2017-10-05 |
| US20230381224A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230381224A1 (en) | Mutant Bordetella Strains and Methods of Use | |
| US12403188B2 (en) | Bordetella strains expressing serotype 3 fimbriae | |
| JP2019513722A5 (enExample) | ||
| JP2005112865A (ja) | 百日咳菌ワクチン用アジュバントとしてのｉｌ−１２ | |
| WO2020049133A1 (en) | Adenylate cyclase catalytic domain deficient bordetella strains | |
| CN112449604A (zh) | 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物 | |
| HK1262896B (zh) | 突变型博德特氏菌属菌株及其使用方法 | |
| HK1262896A1 (en) | Mutant bordetella strains and methods for use | |
| JP6867623B2 (ja) | 百日咳モデル動物およびその作製方法、ならびに百日咳モデル動物を用いた方法 | |
| KR20250038747A (ko) | 만성 폐쇄성 폐질환의 치료를 위한 보르데텔라 균주의 용도 | |
| HK40026630B (zh) | 表达血清3型菌毛的鲍特菌属菌株 | |
| CN116355827A (zh) | 一种治疗结核病的重组卡介苗药物及其应用 | |
| HK40026630A (en) | Bordetella strains expressing serotype 3 fimbriae | |
| Goel | Interleukin-6 Contributes To Immunity Against Bordetella Pertussis. | |
| Guzmàn et al. | Use of Salmonella Spp. Carrier Strains to Deliver Bordetella Pertussis Antigens in Mice using the oral Route |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |